Cypherpunk Technologies is expected to report Q3 2026 revenue of $16.20 million and GAAP EPS of $0.04, with its current $2.55 share price trading well below the $4.90 average analyst price target.
Investors are primarily focused on the valuation and strategic expansion of the company’s Zcash (ZEC) treasury, which is the primary driver of net income volatility via unrealized gains.
This reporting period follows the company's full pivot from biotechnology toward a digital asset treasury model, incorporating Zcash mining operations alongside legacy oncology assets. While crypto performance remains the central narrative, shareholders are also tracking potential updates on the sirexatamab clinical program.